| dc.description.abstract | Introduction : Breast cancer is global problem and commonly in women. Tumor markers can assess tumor progression and response therapy. CEA is used as diagnostic, progression and response therapy. The treatment aims to suppress tumor development. Traditional medicine is considered beneficial and has minimal effect in suppressing tumor. Recent study, extracts of Allium sativum, Curcuma longa and Zingiber officinale consider useful as anti-cancer. However, no studies that discuss combined extraction Allium sativum, Curcuma longa and Zingiber of CEA levels.
Method : Open label clinical trial with one group pretest posttest design , held on June 28, 2021 – July 18, 2021, was conducted at USU Hospital and the population was breast cancer survivor community in Medan. Samples were taken by consecutive sampling. Those who met inclusion and exclusion criteria will be measured for CEA before and after administration of extract Allium sativum, Curcuma longa and Zingiber officinale with dose 500 mg twice a day for 28 days. T test or wilcoxon test was used to measure comparison and analyzed with SPSS version 22th.
Results : 21 subjects who participated, only 20 subjects were analyzed with mean age of 52.7 years, majority stage III A or IIIB (30%). Median CEA before intevention 2.05 (0.70-12.20) g/mL and after intervention of 2.7 (0.8-12.40) g/mL, increasing value and not statistically significant with p>0.05 ( p=0,238).
Conclusion : Median CEA value increased before and after intervention and not statistically significant. | en_US |
